February 7, 2024

“Treatment of Antibody Claims in the U.S. After Amgen v. Sanofi” – IP Strategist

In a February 5, 2024 article published by ALM’s IP Strategist, Harness IP Law Clerk Caley McCarthy and Principal Leanne Rakers discuss three cases involving antibody claiming and enablement that have emerged in the wake of the Supreme Court’s May 2023 decision in Amgen v. Sanofi.

The three cases – decided by the Patent Trial and Appeal Board, a federal appeals court, and a U.S. district court – “have called into question the means by which antibodies may be claimed in the future, if at all,” the authors write.

Based on the outcomes of those cases, McCarthy and Rakers offer guidance to practitioners when drafting patent applications involving antibody claiming.

The full article may be accessed through ALM here, or read as a PDF at the link below.

Harness_ McCarthy and Rakers in ALM’s IP Strategist_February 2024 Issue




Harness IP is celebrating more than 100 years as an intellectual property law firm. Founded in 1921, the firm currently holds a No. 2 ranking from IAM Media for providing counsel to 44 companies with the largest portfolios of issued U.S. patents. The firm also ranks No. 6 for filing the most patent applications on behalf of those companies. Harness IP’s attorneys and IP professionals focus exclusively on patents, trademarks, global IP management, litigation and other IP rights. The firm has offices in metropolitan Dallas, Detroit, St. Louis, and Washington, D.C. Visit www.harnessip.com for more information.